The iconic rise of Viagra has consistently remained a example of pharmaceutical success, yet its future within the broader sector now presents questions about potential yields . Copycat versions are undercutting exclusivity , leading to anxieties that supporting companies closely tied to Viagra's previous position could be a problematic decision ,